产品
编 号：F747529
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1847394-95-9
产品详情
生物活性：
Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer.
体内研究：
Setrusumab (100 mg/kg；每周一次，静脉注射，持续 4 周) 抑制小鼠乳腺癌诱导的骨转移和肌肉无力。Animal Model:8-week-old female immune-compromised CB-17/lcr-Prkdcscid/Rj mice with MDA-MB-231 breast cancer cells injection
Dosage:100 mg/kg
Administration:Intravenous injection; 100 mg/kg once a week for 4 weeks
Result:Significantly inhibited tumor growth in bones and breast cancer cell dissemination into other organs. Inhibited breast cancer-induced osteolytic lesions and subsequent loss of bone mass of the distal femur and of the proximal tibia. Redued phosphorylation of IKKα, IKKβ, and p65.
Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer.
体内研究：
Setrusumab (100 mg/kg；每周一次，静脉注射，持续 4 周) 抑制小鼠乳腺癌诱导的骨转移和肌肉无力。Animal Model:8-week-old female immune-compromised CB-17/lcr-Prkdcscid/Rj mice with MDA-MB-231 breast cancer cells injection
Dosage:100 mg/kg
Administration:Intravenous injection; 100 mg/kg once a week for 4 weeks
Result:Significantly inhibited tumor growth in bones and breast cancer cell dissemination into other organs. Inhibited breast cancer-induced osteolytic lesions and subsequent loss of bone mass of the distal femur and of the proximal tibia. Redued phosphorylation of IKKα, IKKβ, and p65.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备